Targeting CAF to reduce production and release of TGFβ, CXCL12, and matrix metalloproteinases (MPP) can limit cancer cell spreading favored by TGFβ and MPP and the anti-apoptotic effect of CXCL12 on tumor cells. Here, CXCL12 is linked to cancer.